Warfarin anticoagulation and outcomes in patients with atrial fibrillation - A systematic review and metaanalysis

被引:206
|
作者
Reynolds, MW
Fahrbach, K
Hauch, O
Wygant, G
Estok, R
Cella, C
Nalysnyk, L
机构
[1] MetaWorks Inc, Medford, MA USA
[2] AstraZeneca LP, Wilmington, DE USA
关键词
anticoagulation; atrial fibrillation; warfarin;
D O I
10.1378/chest.126.6.1938
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To examine the relationship between international normalized ratio (INR) and Outcomes (major bleeding events and strokes) in patients with atrial fibrillation (AF) receiving anticoagulation with warfarin. Methods: A systematic review and metaanalysis of studies published in the English language between January 1, 1985, and October 30, 2002, was performed. MEDLINE (PubMed), Current Contents, and relevant reference lists were searched. Studies enrolling patients with nonvalvular AF receiving warfarin anticoagulation were eligible for inclusion if they reported stroke and/or major bleeding events in relation to INR, or time spent in therapeutic range. The risk of bleeds in overanticoagulated patients (INR > 3) and the risk of strokes in underanticoagulated patients (INR < 2) were assessed. Results: Twenty-one studies (6,248 patients) met all inclusion criteria. Of the 21 studies, a target conventional INR of 2 to 3 was used in 9 studies. An INR < 2, compared with an INR : 2, was associated with an odds ratio (OR) for ischemic events of 5.07 (95% confidence interval [CI], 2.92 to 8.80). An INR > 3, compared with an INR :5 3, was associated with an OR for bleeding events of 3.21 (95% CI, 1.24 to 8.28). On average, in the four studies with a target INR range of 2 to 3, patients with AF receiving warfarin spent 61% of time within, 13% of time above, and 26% below the therapeutic range. Conclusion: Available evidence indicates that in patients with nonvalvular AF, the risk of ischemic stroke with insufficient warfarin anticoagulation (INR < 2), and the risk of bleeding events with overanticoagulation (INR > 3) are significantly higher relative to patients with AF maintained within the recommended INR of 2 to 3. However, the published data are sparse, heterogeneous, and primarily reported from clinical trials. More studies evaluating clinical outcomes in relation to INR are needed, especially in a real-world setting.
引用
收藏
页码:1938 / 1945
页数:8
相关论文
共 50 条
  • [41] Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia
    Yimer, Nuredin Shiferaw
    Abiye, Alfoalem Araba
    Hussen, Shemsu Umer
    Tadesse, Tamrat Assefa
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [42] Canadian atrial fibrillation anticoagulation study: Were the patients subsequently treated with warfarin?
    Laupacis, A
    Sullivan, K
    Connolly, SJ
    Joyner, C
    Green, M
    Kerr, C
    Morris, A
    Flegel, K
    Mann, E
    Parker, J
    Sussex, B
    Lenis, J
    Gent, M
    Roberts, R
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1996, 154 (11) : 1669 - 1674
  • [43] A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation
    Tait, RC
    Sefcick, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) : 450 - 454
  • [44] The Intersection of Risk and Benefit Is Warfarin Anticoagulation Suitable for Atrial Fibrillation in Patients on Hemodialysis?
    Sood, Manish M.
    Komenda, Paul
    Sood, Amy R.
    Rigatto, Claudio
    Bueti, Joe
    CHEST, 2009, 136 (04) : 1128 - 1133
  • [45] CLINICAL OUTCOMES OF ORAL ANTICOAGULATION AND NO ANTICOAGULATION AMONG HEMODIALYSIS PATIENTS WITH ATRIAL FIBRILLATION
    Polito, Eratosthenes
    Darunday, Grecia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I1209 - I1211
  • [46] Economic Outcomes of Warfarin Discontinuation Among Patients with Atrial Fibrillation
    Spivey, Christina A.
    Liu, Xianchen
    Qiao, Yanru
    Mardekian, Jack
    Parker, Robert B.
    Phatak, Hemant
    Masseria, Cristina
    Kachroo, Sumesh
    Abdulsattar, Younos
    Wang, Junling
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2016, 8 (04) : 141 - 148
  • [47] Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
    Guerin, Annie
    Lin, Jay
    Jhaveri, Mehul
    Wu, Eric Q.
    Yu, Andrew P.
    Cloutier, Martin
    Gauthier, Genevieve
    Alpert, Joseph S.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (02) : 564 - 569
  • [48] Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients
    Sellers, Matthew B.
    Newby, L. Kristin
    AMERICAN HEART JOURNAL, 2011, 161 (02) : 241 - 246
  • [49] Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control
    Bonde, Anders Nissen
    Staerk, Laila
    Lee, Christina J-Y.
    Vinding, Naja Emborg
    Bang, Casper N.
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Lip, Gregory Y. H.
    Olesen, Jonas Bjerring
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (12) : 1357 - 1365
  • [50] Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Borowsky, LH
    Phillips, KA
    Selby, JV
    Singer, DE
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) : 927 - +